ReviewiScience2025
Tumor-resident microbiota in gynecologic malignancies: Molecular mechanisms, clinical correlations, and translational potential.
Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intratumoral microbiota refers to the microbial communities, including bacteria, fungi, and viruses, residing within tumor tissues and forming part of the tumor microenvironment. Evidence shows that it significantly influences solid tumors like colorectal and breast cancer. Advances in sequencing have revealed the specific distribution of these microbes in gynecologic malignancies. Their dynamic composition is closely linked to tumor initiation, progression, and response to therapy, providing new insights for precision medicine. This review examines their molecular mechanisms and clinical relevance, focusing on impacts on diagnosis (e.g., microbial biomarkers), personalized treatment (e.g., modulation of chemotherapy/immunotherapy efficacy), and prognosis (e.g., recurrence risk prediction). It also discusses the translational potential and clinical application challenges of targeting microbiota, aiming to provide new strategies for precision medicine in gynecologic oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.